Effect of desmopressin acetate administration on primary hemostasis in doberman pinschers with type-1 von willebrand disease as assessed by a point-of-care instrument

American Journal of Veterinary Research

Volumn 63, Issue 12, 2002, Pages 1700-1706

  Callan, Mary Beth ^a   Giger, Urs ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN HYDROGEN TARTRATE; ANTITHROMBOCYTIC AGENT; DESMOPRESSIN; DESMOPRESSIN ACETATE; VON WILLEBRAND FACTOR;

ANALYTICAL PARAMETERS; ANEMIA; ANIMAL CELL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; DRUG EFFECT; FEMALE; HEMOSTASIS; IN VITRO STUDY; MALE; MEDICAL ASSESSMENT; MOUTH MUCOSA; NONHUMAN; PROTEIN BLOOD LEVEL; REFERENCE VALUE; THROMBOCYTE AGGREGATION; TIME; VON WILLEBRAND DISEASE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0036916489     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2002.63.1700     Document Type: Article

References (38)

1. Mannucci PM, Ruggeri ZM, Pareti FI, et al. 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand disease. Lancet 1977;1:869-872.
2. Mannucci PM, Canciani MT, Rota L, et al. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand disease. Br J Haematol 1981;47:283-293.
3. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992;82:87-93.
4. Giger U, Dodds WJ. Effect of desmopressin in normal dogs and dogs with von Willebrand's disease. Vet Clin Pathol 1989;18:39-42.
5. Kraus KH, Turrentine MA, Jergens AE, et al. Effect of desmopressin acetate on bleeding times and plasma von Willebrand factor in Doberman Pinscher dogs with von Willebrand's disease. Vet Surg 1989;18:103-109.
6. Meyers KM, Wardrop XJ, Dodds WJ, et al. Effect of exercise, DDAVP and epinephrine on the factor VIII:C/von Willebrand factor complex in normal dogs and von Willebrand factor deficient Doberman Pinscher dogs. Thromb Res 1990;57:97-108.
7. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999;82:35-39.
8. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325-1331.
9. Kerenyi A, Schlammadinger A, Ajzner E, et al. Comparison of PFA-100 closure time and template bleeding time of patients with inherited bleeding disorders causing defective platelet function. Thromb Res 1999;96:487-492.
10. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
11. Harrison P, Robinson MS, Mackie IJ, et al. Performance of the platelet function analyzer PFA-100 in testing abnormalities of primary hemostasis. Blood Coagul Fibrinolysis 1999;10:25-31.
12. Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with a high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand disease and other disorders. Am J Hematol 1999;62:165-174.
13. Callan MB, Giger U. Assessment of a point-of-care instrument for identification of primary hemostatic disorders in dogs. Am J Vet Res 2001;62:652-658.
14. Catalfamo JL, Dodds WJ. Thrombopathias. In: Feldman BF, Zinkl JG, Jain NC, eds. Schalm's veterinary hematology. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2000;1042-1050.
15. Benson RE, Catalfamo JL, Dodds WJ. A multispecies enzyme-linked immunosorbent assay for von Willebrand's factor. J Lab Clin Med 1992;119:420-427.
16. Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer, PFA-100. Semin Thromb Hemost 1995;21:106-112.
17. Kundu SK, Heilmann EJ, Sio R, et al. Characterization of an in vitro platelet function analyzer, PFA-100. Clin Appl Thromb Hemost 1996;2:241-249.
18. Jergens AE, Turrentine MA, Kraus KH, et al. Buccal mucosa bleeding times of healthy dogs and dogs in various pathologic states, including thrombocytopenia, uremia, and von Willebrand's disease. Am J Vet Res 1987;48:1337-1342.
19. Brooks M, Catalfamo J. Buccal mucosa bleeding time is prolonged in canine models of primary hemostatic disorders. Thromb Haemost 1993;70:777-780.
20. Brooks M, Dodds WJ, Raymond SL. Epidemiologic features of von Willebrand's disease in Doberman Pinschers, Scottish Terriers, and Shetland Sheepdogs: 260 cases (1984-1988). J Am Vet Med Assoc 1992;200:1123-1127.
21. Giger U, Brooks M, Dodds WJ, et al. Advances in canine von Willebrand disease, in Proceedings. 18th Annu Meet Vet Med Forum 2000;481-482.
22. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 2000;6:60-67.
23. Nitu-Whalley IC, Griffioen A, Harrington C, et al. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001;66:280-284.
24. Nolan B, White B, Smith J, et al. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol 2000;109:865-869.
25. Cohen AJ, Kessler CM, Ewenstein BM. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centers of North America. Haemophilia 2001;7:235-241.
26. Fressinaud E, Veyradier A, Sigaud M, et al. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyzer at high shear rates. Br J Haematol 1999;106:777-783.
27. Clemmons RM, Meyers KM. Acquisition and aggregation of canine blood platelets: basic mechanisms of function and differences because of breed origin. Am J Vet Res 1984;45:137-144.
28. Feingold HM, Pracek LE, Melarango AJ, et al. Coagulation assays and platelet aggregation patterns in human, baboon, and canine blood. Am J Vet Res 1986;47:2197-2199.
29. Macmillan DC, Sim AK. A comparative study of platelet aggregation in man and laboratory animals. Thromb Diath Haemorrh 1970;24:385-394.
30. Mannucci PM, Remuzzi G, Pusineri E et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:8-12.
31. Mannucci PM, Vicente V, Vianello L, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986;67:1148-1153.
32. Cattaneo M, Tenconi PM, Alberca I, et al. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 1990;64:358-360.
33. Cattaneo M, Pareti FI, Zighetti ML, et al. Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time. J Lab Clin Med 1995;125:540-547.
34. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990;33:39-45.
35. Ruggeri ZM, Mannucci PM, Lombardi R, et al. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982;59:1272-1278.
36. Kraus KH, Turrentine MA, Johnson GS. Multimeric analysis of von Willebrand factor before and after desmopressin acetate (DDAVP) administration intravenously and subcutaneously in male Beagle dogs. Am J Vet Res 1987;48:1376-1379.
37. Balduini CL, Noris P Belletti S, et al. In vitro and in vivo effects of desmopressin on platelet function. Haematologica 1999;84:891-896.
38. McCarroll DR, Waters DC, Steidley KR, et al. Canine platelet von Willebrand factor: quantification and multimeric analysis. Exp Hematol 1988;16:929-937.